Abstract
UV radiation can inactivate viruses such as SARS-CoV-2. However, designing effective UV germicidal irradiation (UVGI) systems can be difficult because the effects of dried respiratory droplets and other fomites on UV light intensities are poorly understood. Numerical modeling of UV intensities inside virus-containing particles on surfaces can increase understanding of these possible reductions in UV intensity. We model UV intensities within spherical approximations of virions randomly positioned within spherical particles. The model virions and dried particles have sizes and optical properties to approximate SARS-CoV-2 and dried particles formed from respiratory droplets, respectively. Wavelengths used are 260 nm (germicidal UVC) and 302 nm (solar UVB). In 5- and 9-μm diameter particles on a surface, illuminated by 260-nm UV light from a direction perpendicular to the surface, 10% and 18% (respectively) of simulated virions are exposed to intensities less than 1/100th of intensities in individually exposed virions (i.e., they are partially shielded). Even for 302-nm light, where the absorption is small, 11% of virions in 9-µm particles have exposures 1/100th those of individually exposed virions. Calculated results show that shielding of virions in a particle can be strongly reduced by illuminating a particle either from multiple widely separated incident directions, or by illuminating a particle rotating in air (because of turbulence, Brownian diffusion, etc.) for a time sufficient to rotate through all orientations with respect to the UV illumination. Because highly UV-reflective paints and surfaces can increase the angular ranges of illumination, they appear likely to be useful for reducing shielding of virions.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The authors acknowledge partial support from the Defense Threat Reduction Agency (DTRA). Hill and Doughty acknowledge internal funding from the US Army DEVCOM Army Research Laboratory.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
No IRB approval needed.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data available upon request.